Holen Sie sich die Stockscreener-App
5.92
8.78%
-0.57
Vorhandelsmarkt:
6.51
0.59
+9.97%
Schlusskurs vom Vortag:
$6.49
Offen:
$6.56
24-Stunden-Volumen:
465.41K
Relative Volume:
2.44
Marktkapitalisierung:
$295.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.02%
1M Leistung:
-19.78%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.88
$6.65
1-Wochen-Bereich:
$5.76
$7.19
52-Wochen-Spanne:
$5.76
$8.23
Helus Pharma Inc Stock (HELP) Company Profile
Firmenname
Helus Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.92 | 323.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Jefferies | Buy |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Helus Pharma Inc Aktie (HELP) Neueste Nachrichten
Helus Pharma appoints Michael Cola as CEO - The Pharma Letter
Helus Pharma Names Michael Cola As CEO For Next Phase Of Growth - bernama
HELUS PHARMA NAMES MICHAEL COLA AS CEO FOR NEXT PHASE OF GROWTH - bernama
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones By Investing.com - Investing.com South Africa
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola - Psychedelic Alpha
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Newswire Canada
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones - Investing.com Canada
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ... - Caledonian Record
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts - Investing.com Canada
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts By Investing.com - Investing.com South Africa
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus - Psychedelic Alpha
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
Psychedelic Funding, Public Markets, and M&A in 2025 - Psychedelic Alpha
The Psychedelic News Feed: January 1218, 2026 - Psychedelic Alpha
Definium points the way forward as MindMed drops old identity - Fierce Pharma
The Psychedelic News Feed: January 0511, 2026 - Psychedelic Alpha
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance
Assessing Cybin’s Valuation As Helus Pharma Uplists To Nasdaq And Joins The Nasdaq Composite Index - Sahm
Helus Pharma Rings the Opening Bell - Nasdaq
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq - bernama
Helus Pharma Rebrands, Debuts On Nasdaq - bernama
Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity ProgramWhat's Changed - simplywall.st
HELUS PHARMA REBRANDS, DEBUTS ON NASDAQ - bernama
Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks
Cybin launches $100 million at-the-market equity program By Investing.com - Investing.com Australia
The New Psychedelics: One Dose, Eight Hours, a Therapist on Standby - Bloomberg
Cybin (CYBN) Receives a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq - TipRanks
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire
Cybin to transfer listing from NYSE American to Nasdaq, rebrand - Investing.com
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire
Cybin to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Business Wire
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
Cybin announces $175 million registered direct offering - marketscreener.com
Cybin Announces $175 Million Registered Direct Offering - Business Wire
Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Cybin to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
Cybin Announces Senior Leadership Changes - Business Wire
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Finanzdaten der Helus Pharma Inc-Aktie (HELP)
Es liegen keine Finanzdaten für Helus Pharma Inc (HELP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):